Recombinant Human ARCN1 293 Cell Lysate

• Cat.No.: ARCN1-8763HCL

Specification

• Description: Antigen standard for archain 1 (ARCN1), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ARCN1 archain 1 [ Homo sapiens ]
• Official Symbol: ARCN1
• Synonyms: ARCN1; archain 1; coatomer protein complex, subunit delta , COPD; coatomer subunit delta; delta-COP; delta-coat protein; coatomer delta subunit; coatomer protein delta-COP; archain vesicle transport protein 1; coatomer protein complex, subunit delta; COPD
• Gene ID: 372
• mRNA Refseq: NM_001142281
• Protein Refseq: NP_001135753
• MIM: 600820
• UniProt ID: P48444
• Chromosome Location: 11q23.3
• Pathway: COPI Mediated Transport, organism-specific biosystem; Golgi to ER Retrograde Transport, organism-specific biosystem; Membrane Trafficking, organism-specific biosystem

Reviews

01/10/2023

the manufacturer can play a vital role in supporting and optimizing the research process.

12/02/2021

ts stability and structural integrity make it an ideal candidate for studying protein structures at high resolution.

09/16/2021

This guarantees that the protein is reliable, consistent, and suitable for experiments, reducing variability and enhancing the reproducibility of findings.

09/01/2021

I am delighted to highly recommend the ARCN1 Protein for researchers seeking excellent performance in Western blotting (WB) experiments and protein electron microscopy structure analysis

04/26/2020

This may include providing detailed protocols, troubleshooting advice, and suggestions for experimental design.

01/21/2020

In WB experiments, the ARCN1 Protein consistently delivers exceptional performance.

06/24/2017

Its exceptional purity and integrity ensure clear and reliable bands, enabling accurate detection and quantification of target proteins.

10/06/2016

The manufacturer can offer technical support and expertise to guide researchers through the experimental process.

Q&As

Has any research been done on potential targeted therapies for SIDSPP caused by ARCN1 mutations?

As the understanding of ARCN1-related disorders is relatively recent, there is limited research on targeted therapies. However, ongoing studies are exploring potential approaches such as gene therapy or pharmacological interventions to address the underlying cellular defects.

Are there any drugs or compounds known to modulate ARCN1 activity?

Currently, there are no specific drugs or compounds known to directly modulate ARCN1 activity. However, there are efforts to develop small molecules that target vesicle trafficking pathways, which indirectly affect ARCN1 function.

Are there any known interactions or partners of the ARCN1 protein?

Yes, the ARCN1 protein interacts with various other proteins in the coatomer complex, such as COPB1, COPB2, and CNIH4, to form stable complexes involved in vesicle trafficking.

Can the ARCN1 protein serve as a therapeutic target for any diseases?

Given its key role in vesicle transport and potential involvement in certain diseases, targeting the ARCN1 protein or its associated complexes could hold therapeutic potential. However, more research is required to explore the feasibility and efficacy of such targeted therapies.

How does the mutation in the ARCN1 gene lead to SIDSPP?

The specific mechanisms by which ARCN1 gene mutations lead to SIDSPP are not yet fully understood. However, it is hypothesized that these mutations disrupt normal vesicle transport within neuronal cells, leading to impaired development and function of the central nervous system.

Are there any specific domains or motifs in the ARCN1 protein that are crucial for its function?

ARCN1 contains multiple domains that are important for its function in vesicle trafficking, such as the β-propeller and α-solenoid domains. These domains mediate interactions with other proteins and vesicle coat components, allowing ARCN1 to be involved in the formation and regulation of COPI-coated vesicles.

How does the ARCN1 protein contribute to normal neuronal development and function?

ARCN1 is involved in the proper sorting and transport of various proteins, lipids, and other cellular components within neurons. This process is crucial for neuronal development, synaptic function, and overall neuronal communication.

Is ARCN1 expression regulated by any specific transcription factors or signaling pathways?

The specific transcription factors or signaling pathways that regulate ARCN1 expression have not been extensively studied. Further research is needed to identify the regulatory elements and mechanisms governing ARCN1 gene expression.

Are there any animal models that have been developed to study the function of ARCN1?

Yes, animal models like mice with ARCN1 gene knockout or specific mutations have been generated to investigate the effects of ARCN1 dysfunction on development and behavior.

Has ARCN1 been implicated in neurodevelopmental disorders other than Severe Intellectual Disability with Progressive Spastic Paraplegia?

To date, ARCN1 alterations have primarily been associated with Severe Intellectual Disability with Progressive Spastic Paraplegia. However, further research is needed to explore its potential involvement in other neurodevelopmental disorders.

What are the symptoms of Severe Intellectual Disability with Progressive Spastic Paraplegia (SIDSPP)?

Individuals with SIDSPP typically experience severe intellectual disability, impaired motor skills, and progressive spastic paraplegia, characterized by stiffness and weakness in the lower extremities.

Is the ARCN1 protein involved in any other cellular processes apart from vesicle transport?

Yes, the ARCN1 protein has been reported to have additional functions, including its involvement in protein glycosylation, membrane traffic regulation, and ER-Golgi transport.

Can mutations or dysregulation of the ARCN1 gene lead to other phenotypic features or conditions?

While ARCN1 alterations have been mostly associated with Severe Intellectual Disability with Progressive Spastic Paraplegia, it is possible that they may contribute to a broader spectrum of phenotypic features and conditions. This could include changes in neuronal morphology, synaptic function, or other cellular processes affected by ARCN1 dysfunction.

Are there any specific cellular pathways or processes that ARCN1 is known to be involved in?

ARCN1 is primarily involved in intracellular vesicle trafficking, particularly in the formation and maintenance of coat protein complex I (COPI) vesicles. COPI-mediated vesicular transport is essential for protein and lipid sorting, maintenance of organelle integrity, and intra-Golgi and retrograde Golgi-to-ER transport.

Are mutations in the ARCN1 gene associated with any diseases?

Yes, mutations in the ARCN1 gene have been linked to a rare neurodevelopmental disorder known as Severe Intellectual Disability with Progressive Spastic Paraplegia (SIDSPP).

Is there any evidence of ARCN1 protein playing a role in synaptic transmission?

While the exact role of ARCN1 in synaptic transmission is not fully understood, studies have suggested its involvement in regulating the release of neurotransmitters and the recycling of synaptic vesicles, which are essential processes for effective synaptic transmission.

Are there any known alternative splicing variants or isoforms of the ARCN1 gene?

Yes, alternative splicing of the ARCN1 gene can generate multiple isoforms. However, the functional significance of these isoforms and their specific roles in different tissues or conditions is still not well characterized.

Has the ARCN1 protein been implicated in any other diseases or conditions?

Apart from its association with Severe Intellectual Disability with Progressive Spastic Paraplegia, ARCN1 alterations have not been extensively linked to other diseases. However, some studies have suggested potential involvement of ARCN1 in cancer progression and neurodegenerative disorders, although further research is needed to establish these connections.

Are there any known post-translational modifications of the ARCN1 protein?

While there is limited information available regarding post-translational modifications of ARCN1, it has been suggested that ARCN1 may undergo phosphorylation, acetylation, and ubiquitination, which may regulate its function and stability.

How does the ARCN1 protein contribute to vesicle transport?

ARCN1, as part of the coatomer complex, helps in the formation of coat protein complex I (COPI) vesicles, which mediate retrograde transport from the Golgi to the endoplasmic reticulum and also within the Golgi itself.